Eris Lifesciences Reports 13% Revenue Growth In Q2FY27; Margin Slips | CNBC TV18
CNBC-TV18 · 27 Oct 2026 · 8 min
Management interview of Eris Lifesciences Ltd (ERIS), with 5 key numbers discussed.
- Amit Bakshi, CMD, Eris Lifesciences
Eris Lifesciences expects gross margins to improve by 150-200 bps in H2, supported by in-house biologic production. Blended exit margins are guided at around 35%, with domestic branded formulations margins at 36-37%. The company maintains an overall growth guidance of approximately 13%, even as international business faces GMP remediation delays. Debt reduction will accelerate as the capex cycle winds down, targeting a Rs 1.5-2bn debt repayment in H2.